Bifunctional CD4-DC-SIGN fusion proteins demonstrate enhanced avidity to gp120 and inhibit HIV-1 infection and dissemination

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4640-4649

  Du, Tao ^a,b   Hu, Kai ^a,b   Yang, Jun ^a,f   Jin, Jing ^c   Li, Chang ^a,b   Stieh, Daniel ^d   Griffin, George E ^d   Shattock, Robin J ^e   Hu, Qinxue ^a,d  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f Zhengzhou Tobacco Research Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD209 ANTIGEN; CD4 ANTIGEN; CD4 LINKER DC SIGN PROTEIN; GLYCOPROTEIN GP 120; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DENDRITIC CELL; DRUG BINDING; DRUG TARGETING; EXPLANT; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; UTERINE CERVIX; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

ANTIGENS, CD4; BINDING SITES; CELL ADHESION MOLECULES; CELL LINE; DENDRITIC CELLS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; LECTINS, C-TYPE; PLASMIDS; PRIMARY CELL CULTURE; RECEPTORS, CELL SURFACE; RECEPTORS, VIRUS; RECOMBINANT FUSION PROTEINS; SOLUBILITY; TRANSFECTION;

EID: 84865407002     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00623-12     Document Type: Article

References (57)

1. Abdiche Y, Malashock D, Pinkerton A, Pons J. 2008. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal. Biochem. 377:209-217.
2. Allaway GP, et al. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 11:533-539.
3. Arrighi JF, et al. 2004. DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J. Exp. Med. 200:1279-1288.
4. Ashkenazi A, et al. 1990. Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis. Proc. Natl. Acad. Sci. U. S. A. 87:7150-7154.
5. Baleux F, et al. 2009. A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry. Nat. Chem. Biol. 5:743-748.
6. Balzarini J. 2007. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat. Rev. Microbiol. 5:583-597. (Pubitemid 47074114)
7. Berzi A, et al. 2012. A glycomimetic compound inhibits DC-SIGN-mediated HIV infection in cellular and cervical explant models. AIDS 26:127-137.
8. Cerutti N, et al. 2010. Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange. J. Biol. Chem. 285:25743-25752.
9. Chen W, Xiao X, Wang Y, Zhu Z, Dimitrov DS. 2010. Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res. 88:107-115.
10. Chen W, Zhu Z, Feng Y, Dimitrov DS. 2008. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc. Natl. Acad. Sci. U. S. A. 105:17121-17126.
11. DeVico A, et al. 2007. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc. Natl. Acad. Sci. U. S. A. 104:17477-17482. (Pubitemid 350219863)
12. de Witte L, et al. 2007. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc. Natl. Acad. Sci. U. S. A. 104:19464-19469.
13. Esser U, et al. 2000. Molecular function of the CD4 D1 domain in coreceptor-mediated entry by HIV type 1. AIDS Res. Hum. Retroviruses 16:1845-1854.
14. Ferrer M, et al. 1997. Construction and characterization of a radio-iodinatable mutant of recombinant human CD4. J. Immunol. Methods 210:215-225. (Pubitemid 28266565)
15. Fouts T, et al. 2002. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc. Natl. Acad. Sci. U. S. A. 99:11842-11847. (Pubitemid 34994486)
16. Garbett NC, Mekmaysy CS, Chaires JB. 2010. Sedimentation velocity ultracentrifugation analysis for hydrodynamic characterization of G-quadruplex structures. Methods Mol. Biol. 608:97-120.
17. Geijtenbeek TB, den Dunnen J, Gringhuis SI. 2009. Pathogen recognition by DC-SIGN shapes adaptive immunity. Future Microbiol. 4:879-890.
18. Geijtenbeek TB, Gringhuis SI. 2009. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 9:465-479.
19. Geijtenbeek TB, et al. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587-597.
20. Geijtenbeek TB, et al. 2002. Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1. J. Biol. Chem. 277:11314-11320. (Pubitemid 34952896)
21. Geijtenbeek TB, van Kooyk Y. 2003. DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr. Top. Microbiol. Immunol. 276:31-54. (Pubitemid 36538346)
22. Guo Y, et al. 2004. Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR. Nat. Struct. Mol. Biol. 11:591-598. (Pubitemid 38823524)
23. Gurney KB, et al. 2005. Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J. Virol. 79:5762-5773. (Pubitemid 40548245)
24. Hansen JE, Lund O, Nielsen JO, Brunak S. 1996. Prediction of the secondary structure of HIV-1 gp120. Proteins 25:1-11. (Pubitemid 26156337)
25. Hijazi K, et al. 2011. DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4. PLoS One 6:e28307.
26. Hofmann H, Pohlmann S. 2011. DC-SIGN: access portal for sweet viral killers. Cell Host Microbe 10:5-7.
27. Hong PW, Nguyen S, Young S, Su SV, Lee B. 2007. Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120. J. Virol. 81:8325-8336. (Pubitemid 47101517)
28. Hu Q, et al. 2004. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J. Exp. Med. 199:1065-1075. (Pubitemid 38619903)
29. Hu Q, et al. 2005. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization. J. Mol. Biol. 350:699-712. (Pubitemid 40848668)
30. Hu Q, Younson J, Griffin GE, Kelly C, Shattock RJ. 2006. Pertussis toxin and its binding unit inhibit HIV-1 infection of human cervical tissue and macrophages involving a CD14 pathway. J. Infect. Dis. 194:1547-1556. (Pubitemid 44851896)
31. Hu QX, et al. 2000. Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J. Virol. 74:11858-11872.
32. Huang X, et al. 2012. Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Virology 423:97-106.
33. Ivey-Hoyle M, et al. 1991. Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4. Proc. Natl. Acad. Sci. U. S. A. 88:512-516. (Pubitemid 21915495)
34. Jameson B, et al. 2002. Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J. Virol. 76:1866-1875. (Pubitemid 34094633)
35. Labrijn AF, et al. 2003. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77:10557-10565. (Pubitemid 37129699)
36. Lagenaur LA, Villarroel VA, Bundoc V, Dey B, Berger EA. 2010. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology 7:11.
37. Lambert AA, Gilbert C, Richard M, Beaulieu AD, Tremblay MJ. 2008. The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood 112:1299-1307.
38. Lee B, et al. 2001. cis expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. J. Virol. 75:12028-12038. (Pubitemid 33115875)
39. Ma X, Hu Q, Cui T, Yang J, Zhang Z. 2004. Expression, purification and biological analysis of soluble DC-SIGN. Chin J. Microbiol. Immunol. 24: 67-71. (Pubitemid 38506563)
40. Marzi A, et al. 2007. Modulation of HIV and SIV neutralization sensitivity by DC-SIGN and mannose-binding lectin. Virology 368:322-330. (Pubitemid 350016227)
41. McDonald D, et al. 2003. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 300:1295-1297. (Pubitemid 36618241)
42. Naarding MA, et al. 2005. Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J. Clin. Invest. 115:3256-3264. (Pubitemid 41567590)
43. Peakman M, Senaldi G, Foote N, McManus TJ, Vergani D. 1992. Naturally occurring soluble CD4 in patients with human immunodeficiency virus infection. J. Infect. Dis. 165:799-804.
44. Plazolles N, et al. 2011. Pivotal advance: the promotion of soluble DCSIGN release by inflammatory signals and its enhancement of cytomegalovirus-mediated cis-infection of myeloid dendritic cells. J. Leukoc. Biol. 89:329-342.
45. Poignard P, Saphire EO, Parren PW, Burton DR. 2001. gp120: biologic aspects of structural features. Annu. Rev. Immunol. 19:253-274. (Pubitemid 32368036)
46. Requena M, et al. 2008. Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous immunoglobulins. Immunology 123:508-518. (Pubitemid 351280964)
47. Schuck P. 2000. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys. J. 78:1606-1619. (Pubitemid 30141584)
48. Schutten M, Andeweg AC, Bosch ML, Osterhaus AD. 1995. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand. J. Immunol. 41:18-22.
49. Serrano-Gomez D, et al. 2008. Structural requirements for multimerization of the pathogen receptor dendritic cell-specific ICAM3-grabbing non-integrin (CD209) on the cell surface. J. Biol. Chem. 283:3889-3903.
50. Sexton A, et al. 2006. Transgenic plant production of Cyanovirin-N, an HIV microbicide. FASEB J. 20:356-358. (Pubitemid 46671170)
51. Shearer WT, et al. 2000. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J. Infect. Dis. 182: 1774-1779.
52. Stamatatos L, Werner A, Cheng-Mayer C. 1994. Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1. J. Virol. 68:4973-4979. (Pubitemid 24226563)
53. Su SV, et al. 2004. DC-SIGN binds to HIV-1 glycoprotein 120 in a distinct but overlapping fashion compared with ICAM-2 and ICAM-3. J. Biol. Chem. 279:19122-19132. (Pubitemid 38623343)
54. Sullivan N, et al. 1998. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J. Virol. 72:6332-6338. (Pubitemid 28323943)
55. Turville SG, et al. 2002. Diversity of receptors binding HIV on dendritic cell subsets. Nat. Immunol. 3:975-983. (Pubitemid 35154012)
56. West AP, Jr, et al. 2010. Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents. J. Virol. 84:261-269.
57. WuL. 2008. Biology of HIV mucosal transmission. Curr. Opin. HIV AIDS 3:534-540.